KR101995394B1 - Antimicrobial composition against pet turtle-borne pathogenic bacteria containing lavender essential oil as effective component - Google Patents
Antimicrobial composition against pet turtle-borne pathogenic bacteria containing lavender essential oil as effective component Download PDFInfo
- Publication number
- KR101995394B1 KR101995394B1 KR1020170175619A KR20170175619A KR101995394B1 KR 101995394 B1 KR101995394 B1 KR 101995394B1 KR 1020170175619 A KR1020170175619 A KR 1020170175619A KR 20170175619 A KR20170175619 A KR 20170175619A KR 101995394 B1 KR101995394 B1 KR 101995394B1
- Authority
- KR
- South Korea
- Prior art keywords
- aeromonas
- essential oil
- pathogenic bacteria
- lavender essential
- antimicrobial composition
- Prior art date
Links
- 244000178870 Lavandula angustifolia Species 0.000 title claims abstract description 39
- 235000010663 Lavandula angustifolia Nutrition 0.000 title claims abstract description 39
- 239000001102 lavandula vera Substances 0.000 title claims abstract description 39
- 235000018219 lavender Nutrition 0.000 title claims abstract description 39
- 244000052616 bacterial pathogen Species 0.000 title claims abstract description 37
- 239000000341 volatile oil Substances 0.000 title claims abstract description 35
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 241000270666 Testudines Species 0.000 claims abstract description 20
- 241001486707 Aeromonas dhakensis Species 0.000 claims abstract description 11
- 239000004599 antimicrobial Substances 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 238000001256 steam distillation Methods 0.000 claims description 5
- 241001138501 Salmonella enterica Species 0.000 abstract description 15
- 241000607516 Aeromonas caviae Species 0.000 abstract description 13
- 241000589516 Pseudomonas Species 0.000 abstract description 12
- 241000607528 Aeromonas hydrophila Species 0.000 abstract description 10
- 230000003115 biocidal effect Effects 0.000 abstract description 7
- 241000607534 Aeromonas Species 0.000 description 17
- 239000003242 anti bacterial agent Substances 0.000 description 11
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000006150 trypticase soy agar Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 241001377010 Pila Species 0.000 description 2
- 241000408228 Pseudemys concinna Species 0.000 description 2
- 241000270708 Testudinidae Species 0.000 description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 2
- 241001459907 Trachemys scripta scripta Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 2
- 229960000603 cefalotin Drugs 0.000 description 2
- 229960002682 cefoxitin Drugs 0.000 description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 229960002182 imipenem Drugs 0.000 description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960000210 nalidixic acid Drugs 0.000 description 2
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 238000002768 Kirby-Bauer method Methods 0.000 description 1
- 241000033974 Mauremys sinensis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001247288 Ocadia Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009034 developmental inhibition Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 229910001751 gemstone Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000001198 melaleuca alternifolia leaf oil Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 라벤더 에센셜 오일을 유효성분으로 함유하는 애완용 거북으로부터 분리한 병원성 세균에 대한 항균용 조성물에 관한 것으로, 보다 상세하게는 본 발명에서는 라벤더 에센셜 오일이 애완 거북으로부터 분리된 병원성 세균인 에어로모나스 캐비애(Aeromonas caviae), 에어로모나스 드하켄시스(Aeromonas dhakensis), 에어로모나스 하이드로필라(Aeromonas hydrophila) 및 살모넬라 엔테리카(Salmonella enterica)에 대해 우수한 항균 활성을 나타내는 것을 확인하였고, 상기 병원성 세균들이 다중항생제내성을 지닌 균주인 점을 고려하면, 본 발명의 라벤더 에센셜 오일은 상기 병원성 세균의 생육을 저해하는데 더욱 유용하게 사용될 수 있다. The present invention relates to an antimicrobial composition for pathogenic bacteria isolated from pet turtles containing lavender essential oil as an active ingredient. More particularly, the present invention relates to a composition for antimicrobial treatment of pathogenic bacteria, Sorrow ( Aeromonas caviae), Pseudomonas aero de Hakan sheath (Aeromonas dhakensis), Pseudomonas aero dihydro-pillar (Aeromonas hydrophila and Salmonella enterica , and considering that the pathogenic bacterium is a strain having multiple antibiotic resistance, the lavender essential oil of the present invention is effective for the growth of the pathogenic bacteria It can be used more effectively.
Description
본 발명은 라벤더 에센셜 오일을 유효성분으로 함유하는 애완용 거북으로부터 분리한 병원성 세균에 대한 항균용 조성물에 관한 것이다.The present invention relates to an antimicrobial composition for pathogenic bacteria isolated from pet turtles containing lavender essential oil as an active ingredient.
최근 애완동물의 사육이 어린이들 사이에서 큰 인기를 끌고 있다. 애완동물의 소유 및 이들과의 상호작용은 어린이들의 정서 발달과 생명의 신비감을 일깨워 주는 교육효과도 높은 것으로 알려지며, 그 종류도 개, 고양이에서부터 거북이, 도마뱀, 지네, 거미, 전갈, 장수하늘소에 이르기까지 나날이 다양해지고 있다. 그러나 애완동물에는 동물에게는 병을 일으키지 않지만 사람에게는 각종 질병을 유발하는 병원성 세균이 존재할 수 있다. 특히, 거북이와 같은 파충류는 사람에게 식중독과 장티푸스를 일으키는 병원성 세균인 살모넬라균을 가지고 있어 애완동물로 기를 경우 감염의 우려가 있다. 면역력이 약한 어린이와 노약자에게는 특히 위험할 수 있으며, 외국의 경우 거북이에 의한 감염으로 사망한 사례가 보고되기도 하였다. Recently, pet breeding has become very popular among children. The possession and interactions with pets are known to be highly effective in educating children's emotional development and the mystery of life. They are also known as dogs, cats, turtles, lizards, centipedes, spiders, scorpions, It is becoming diverse from day to day. However, pets do not cause disease in animals, but humans may have pathogenic bacteria that cause various diseases. In particular, reptiles such as turtles have Salmonella, a pathogenic bacterium that causes food poisoning and typhoid in humans. It may be particularly dangerous for children with low immunity and for the elderly, and in some cases, deaths due to infection by turtles have been reported in foreign countries.
라벤더(Lavender)는 꿀풀과(Lamiaceae 또는 Labiatae)라 부르는 식물과에 속하는 식물로 약 20여 종을 포함하고 있다. 그 중 대표적으로 라벤둘라 안구스티폴리아(Lavendula angustifolia)가 라벤더 에센셜 오일의 제조에 이용된다. 프랑스, 스페인 또는 고산지대에서 재배되며 주로 꽃봉오리에서 수증기 증류법 또는 용매 추출법을 이용하여 에센셜 오일을 추출한다. 로마시대부터 향수와 향료의 원료 등으로 사용된 라벤더 에센셜 오일은 인체에 독성이 낮고 방부, 항염, 살충 효과 및 상처 치유 효과를 가지고 있다고 알려져 있다. 이와 같은 효능 및 효과를 가지고 있는 라벤더 에센셜 오일은 바디워시와 같은 세정제나 방향제 등에 많이 이용된다. 또한, 희석하지 않은 원액 그대로는 이용하지 않는 대부분의 에센셜 오일과 달리 라벤더 에센셜 오일은 티트리(Melaleuca alternifolia) 오일과 더불어 화상, 여드름, 피부 발진 등의 제한된 경우에 한하여 희석하지 않고 피부에 직접 사용하기도 한다. 아로마 테라피적 관점에서의 라벤더 에센셜 오일은 몸과 마음을 조화롭게 하여 건강을 유지하고 회복 기능을 강화시키며, 정서적으로는 스트레스, 불안, 우울증의 해소, 불면증이나 두통, 편두통의 치료에 사용된다.Lavender (Lavender) is a plant belonging to the family Lamiaceae or Labiatae and contains about 20 species. Among them, Lavendula angustifolia ( Lavendula angustifolia ) is used for the production of lavender essential oil. It is cultivated in France, Spain or alpine region and extracts essential oil mainly by using steam distillation method or solvent extraction method in bud. Lavender essential oils used as raw materials for perfumes and fragrances since Roman times are low in human toxicity, and are known to have preservative, anti-inflammatory, insecticidal and wound healing effects. Lavender essential oils, which have such efficacy and effectiveness, are widely used in cleaning agents and fragrances such as bodywashes. In addition, unlike most essential oils that are not used as undiluted undiluted concentrate, lavender essential oils are used in combination with Melaleuca alternifolia oil, as well as in the limited cases of burns, acne, and skin rashes, do. Lavender Essential Oil from the Aromatherapy Perspective is used to balance body and mind to maintain health and enhance recovery, emotionally to relieve stress, anxiety, depression, insomnia, headache, and migraine.
한편, 한국공개특허 제2004-0087380호는 구강세균에 대한 항균효과가 우수한 에센셜 오일 조성물을 개시하고 있으며, 한국공개특허 제2009-0028275호는 에센셜 오일 조합을 주성분으로 하는 피부 노화방지와 주름개선 효과를 갖는 화장료 및 그 제조방법을 개시하고 있다. 하지만, 본 발명의 라벤더 에센셜 오일을 유효성분으로 함유하는 애완용 거북으로부터 분리한 병원성 세균에 대한 항균용 조성물에 대해 아직까지 개시된 바가 없다.Korean Patent Laid-Open Publication No. 2004-0087380 discloses an essential oil composition having excellent antimicrobial effect against oral bacteria. Korean Patent Laid-Open Publication No. 2009-0028275 discloses a composition for preventing skin aging and improving wrinkles comprising an essential oil combination as a main component And a process for producing the same. However, the antibacterial composition for pathogenic bacteria isolated from a pet turtle containing the lavender essential oil of the present invention as an effective ingredient has not yet been disclosed.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명자들은 수증기 증류법(steam distillation)을 이용하여 라벤더의 꽃으로부터 추출한 라벤더 에센셜 오일을 애완 거북으로부터 분리한 병원성 세균인 에어로모나스 캐비애(Aeromonas caviae), 에어로모나스 드하켄시스(Aeromonas dhakensis), 에어로모나스 하이드로필라(Aeromonas hydrophila) 및 살모넬라 엔테리카(Salmonella enterica)에 대해 각각 처리한 결과, 이들의 생육을 효과적으로 저해하는 것을 확인함으로써, 본 발명을 완성하였다. SUMMARY OF THE INVENTION The present invention has been made in view of the above-described needs, and the present inventors have found that the use of steam distillation to remove lavender essential oils from lavender flowers from aeromonas cavaea ( Aeromonas caviae , Aeromonas de Hacensis dhakensis ), Aeromonas hydrofilas ( Aeromonas hydrophila , and Salmonella enterica , respectively. As a result, the present inventors have completed the present invention by confirming that they effectively inhibit their growth.
상기 과제를 해결하기 위하여, 본 발명은 라벤더 에센셜 오일을 유효성분으로 함유하는 애완용 거북으로부터 분리한 병원성 세균에 대한 항균용 조성물을 제공한다. In order to solve the above problems, the present invention provides an antimicrobial composition for pathogenic bacteria separated from a pet turtle containing lavender essential oil as an active ingredient.
본 발명에서는 라벤더 에센셜 오일이 애완 거북으로부터 분리된 병원성 세균인 에어로모나스 캐비애(Aeromonas caviae), 에어로모나스 드하켄시스(Aeromonas dhakensis), 에어로모나스 하이드로필라(Aeromonas hydrophila) 및 살모넬라 엔테리카(Salmonella enterica)에 대해 우수한 항균 활성을 나타내는 것을 확인하였고, 상기 병원성 세균들이 다중항생제내성을 지닌 균주인 점을 고려하면, 본 발명의 라벤더 에센셜 오일은 상기 병원성 세균의 생육을 저해하는데 더욱 유용하게 사용될 수 있다. In the present invention, lavender essential oil is a pathogenic bacterium isolated from pet turtle, Aeromonas caviae), Pseudomonas aero de Hakan sheath (Aeromonas dhakensis), Pseudomonas aero dihydro-pillar (Aeromonas hydrophila and Salmonella enterica , and considering that the pathogenic bacterium is a strain having multiple antibiotic resistance, the lavender essential oil of the present invention is effective for the growth of the pathogenic bacteria It can be used more effectively.
본 발명의 목적을 달성하기 위하여, 본 발명은 라벤더 에센셜 오일을 유효성분으로 함유하는 애완용 거북으로부터 분리한 병원성 세균에 대한 항균용 조성물을 제공한다. In order to accomplish the object of the present invention, the present invention provides an antimicrobial composition for a pathogenic bacterium isolated from a pet turtle containing lavender essential oil as an active ingredient.
본 발명의 "항균(antimicrobial)"의 의미는 어떤 농도에서 미생물의 성장 또는 생존을 감소, 방지, 억제, 또는 제거하는 능력을 의미한다. The term " antimicrobial "of the present invention means the ability to reduce, prevent, inhibit, or eliminate the growth or survival of a microorganism at any concentration.
본 발명의 "항균용 조성물"은 세균과 같은 미생물의 생육을 저해하는 활성을 가진 조성물로서, 항미생물제를 총칭하는 의미인 항생제와 같은 의미일 수 있고, 항균 효과가 요구되는 다양한 분야에 사용되는 모든 형태가 포함될 수 있으며, 예를 들어, 의약품, 의약외품, 식품 첨가제 또는 사료 첨가제 등의 형태일 수 있다.The "antimicrobial composition" of the present invention is a composition having an activity of inhibiting the growth of microorganisms such as bacteria, and may be the same as an antibiotic, which is generically referred to as an antimicrobial agent. And may be in the form of pharmaceuticals, quasi-drugs, food additives or feed additives, for example.
본 발명의 "함유하는(comprising)" 용어는 포함하는 것에 한정되지 않으며, 일예로 다른 첨가제, 성분, 지수 또는 단계와 같은 것을 제외하지 않는다.The term " comprising "of the present invention is not limited to inclusive, and does not exclude, for example, other additives, ingredients, exponents, or steps.
본 발명의 일 구현 예에 따른 병원성 세균에 대한 항균용 조성물에서, 상기 병원성 세균은 에어로모나스 캐비애(Aeromonas caviae), 에어로모나스 드하켄시스(Aeromonas dhakensis), 에어로모나스 하이드로필라(Aeromonas hydrophila) 및 살모넬라 엔테리카(Salmonella enterica)로 이루어진 군으로부터 선택된 어느 하나 이상인 것일 수 있으나, 이에 제한되지 않는다.In an antimicrobial composition for a pathogenic bacterium according to an embodiment of the present invention, the pathogenic bacterium is Aeromonas caviae), Pseudomonas aero de Hakan sheath (Aeromonas dhakensis), Pseudomonas aero dihydro-pillar (Aeromonas hydrophila , and Salmonella enterica . However, the present invention is not limited thereto.
또한, 본 발명의 일 구현 예에 따른 병원성 세균에 대한 항균용 조성물에서, 상기 병원성 세균은 리버쿠터 거북(Pseudemys concinna), 보석 거북(Ocadia sinensis) 또는 노란배 거북(Trachemys scripta scripta)으로부터 분리된 것일 수 있으나, 이에 제한되지 않는다.In the antimicrobial composition for pathogenic bacteria according to an embodiment of the present invention, the pathogenic bacterium is a Pseudemys concinna ), gem tortoise ( Ocadia sinensis ) or yellow tortoise ( Trachemys scripta scripta ), but is not limited thereto.
또한, 본 발명의 일 구현 예에 따른 병원성 세균에 대한 항균용 조성물에서, 상기 라벤더 에센셜 오일은 수증기 증류법(steam distillation)을 이용하여 라벤더의 꽃으로부터 추출한 것일 수 있으나, 이에 제한되지 않는다.In addition, in the antimicrobial composition for pathogenic bacteria according to an embodiment of the present invention, the lavender essential oil may be extracted from flowers of lavender using steam distillation, but is not limited thereto.
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.
재료 및 방법Materials and methods
1. 병원성 세균 및 라벤더 1. Pathogenic bacteria and lavender 에센셜Essential 오일 oil
리버쿠터 거북(Pseudemys concinna), 보석 거북(Ocadia sinensis) 및 노란배 거북(Trachemys scripta scripta)으로부터 분리한 4종의 병원성 세균을 시험에 사용하였으며, 각 세균당 사용한 균주(strain) 수는 다음과 같다; 에어로모나스 캐비애(Aeromonas caviae)(n=3), 에어로모나스 드하켄시스(Aeromonas dhakensis)(n=2), 에어로모나스 하이드로필라(Aeromonas hydrophila)(n=5) 및 살모넬라 엔테리카(Salmonella enterica)(n=6). 본 발명의 라벤더 에센셜 오일(Aromarant, Rottingen, Germany)은 불가리아산 라벤더의 꽃을 수증기 증류법(steam distillation)을 이용하여 추출한 것으로, 순도 100%인 것을 사용하였다.River Kooter Turtle ( Pseudemys concinna ), Jewel Turtle ( Ocadia Four strains of pathogenic bacteria isolated from the sinensis and Trachemys scripta scripta were used for the test. The number of strains used for each bacterium was as follows; Pseudomonas aero cache sorrow (Aeromonas caviae) (n = 3 ), Pseudomonas aero de Hakan sheath (Aeromonas dhakensis ) (n = 2), Aeromonas hydrofilas ( Aeromonas hydrophila (n = 5) and Salmonella enterica (n = 6). The lavender essential oil of the present invention (Aromarant, Rottingen, Germany) was obtained by extracting flowers of Bulgarian lavender using steam distillation, and a purity of 100% was used.
2. 디스크확산시험(Disc Diffusion Test)2. Disc Diffusion Test
시험에 사용된 병원성 세균들은 TSA(tryptic soy agar)(MB Cell, LA, CA) 배지에 접종 후 37℃에서 24시간 동안 배양하였다. 각 균주들로부터 집락 하나를 떼어내어 엔돌프 튜브(Eppendorf tube)에 담은 0.5mL의 멸균 식염수와 혼합하여 MacFarland No. 0.5(1.5 × 106 CFU/mL)에 준하는 탁도의 균주 현탁액을 제조하였다. 상기 현탁액을 멸균된 면봉에 적셔 뮬러-힌톤 아가(Mueller-Hinton agar; MB Cell, LA, CA) 배지에 도말하였으며, 라벤더 에센셜 오일은 4개의 농도(100%, 50%, 25% 및 10%)로 준비한 후 지름 6mm의 멸균처리된 종이 디스크(Advantec, Tokyo, Japan)에 적셔 접종된 뮬러-힌톤 아가 배지에 하나씩 붙였다. 라벤더 에센셜 오일이 증발하는 것을 방지하기 위해 각 배지를 플라스틱 랩으로 감싼 후에 37℃에서 24시간 동안 배양하였다.The pathogenic bacteria used in the test were inoculated into TSA (tryptic soy agar) (MB Cell, LA, CA) medium and incubated at 37 ° C for 24 hours. One colony was removed from each strain and mixed with 0.5 mL of sterile saline in an Eppendorf tube, 0.5 (1.5 x 10 6 CFU / mL). The suspension was applied to a Mueller-Hinton agar (MB Cell, LA, CA) medium by dipping on a sterilized cotton swab and the lavender essential oil had four concentrations (100%, 50%, 25% and 10% , And then attached to Mueller-Hinton agar medium inoculated on a sterilized paper disk (Advantec, Tokyo, Japan) having a diameter of 6 mm. To prevent evaporation of lavender essential oil, each medium was wrapped in plastic wrap and incubated at 37 ° C for 24 hours.
또한, 항생제 디스크를 사용한 시험도 상기와 같이 동일한 방법으로 실시하였으며, CLSI(Clinical Laboratory Standards Institute)의 설명에 따라 수행하였다. 페니실린계 항생제를 대표하여 암피실린(ampicillin; 10㎍) 및 아목시실린(amoxicillin; 30㎍)을, 세팔로스포린(cephalosporin)계 항생제를 대표하여 세폭시틴(cefoxitin; 30㎍), 세파로신(cephalothin; 30㎍) 및 세프트리약손(ceftriaxone; 30㎍)을, 카르바페넴(carbapenem)계 항생제를 대표하여 이미페넴(imipenem; 10㎍)을, 아미노글리코시드(aminoglycoside)계 항생제를 대표하여 겐타마이신(gentamicin; 10㎍) 및 스트렙토마이신(streptomycin; 10㎍)을, 그리고 퀴놀론(quinolone)계 항생제를 대표하여 날리딕스산(nalidixic acid; 30㎍) 및 시프로플록사신(ciprofloxacin; 5㎍)을 사용하였다.In addition, the test using the antibiotic disc was carried out in the same manner as described above, and was performed according to the description of CLSI (Clinical Laboratory Standards Institute). Ampicillin (10 μg) and amoxicillin (30 μg) are representative of penicillin antibiotics and cefoxitin (30 μg), cephalothin (30 μg) are representative of cephalosporin antibiotics. 30 μg) and ceftriaxone (30 μg) were intraperitoneally injected with imipenem (10 μg) on behalf of carbapenem antibiotics and gentamicin (10 μg) on the basis of aminoglycoside antibiotics 10 μg streptomycin and 10 μg streptomycin and nalidixic acid 30 μg and ciprofloxacin 5 μg as quinolone antibiotics.
3. 3. 다중항생제내성Multiple antibiotic resistance 지표(Multiple Antibiotics Resistance Index; MAR Index) Multiple Antibiotics Resistance Index (MAR Index)
다중항생제내성 지표는 참고문헌(Adenaike et al., 2016, Journal of Natural Sciences Research, Vol.6)에서 언급한 대로 계산하였으며, 지표 값을 계산하는 데 사용된 균주는 항균 디스크 확산 시험 결과에서 각종으로부터 가장 강한 내성을 보이는 1종의 균주를 선택하여 MAR 지표 값을 계산하였다. MAR 지표 값은 균주가 노출된 항생제의 총수에 대해 내성을 나타내는 항생제 수의 비율로 계산되었다.The antimicrobial susceptibility index was calculated as described in references (Adenaike et al ., 2016, Journal of Natural Sciences Research, Vol. 6) One of the most resistant strains was selected and the MAR index value was calculated. The MAR index value was calculated as the ratio of the number of antibiotics that showed resistance to the total number of exposed antibiotics.
4. 최소발육저지농도(4. Minimum development inhibition concentration ( MICMIC ) 및 최소살균농도(MBC) 시험) And minimum sterilization concentration (MBC) test
MIC(Minimum Inhibitory Concentratio) 시험은 96-웰 마이크로티터 플레이트에 액체배지희석법을 이용하여 실시하였다. 구체적으로, 5%의 DMSO(dimethyl sulfoxide)가 포함된 100㎕의 더블-스트렝스(double-strength) 물러-힌톤 액체배지(MB Cell, LA, CA) 일부를 96-웰 마이크로티터 플레이트에 첨가하였으며, 라벤더 에센셜 오일은 2%부터 0.0156%(v/v)로 설정한 후 96-웰 마이크로티터 플레이트에 분주하고, 모든 웰에 병원성 세균 현탁액 100㎕를 접종하였다. 결과를 보다 객관적으로 평가하기 위해, 병원성 세균 및 액체배지만을 담은 양성대조군(positive control)과 라벤더 에센셜 오일 및 액체배지만을 담은 음성대조군(negative control)도 제조하였으며, 대조군 및 실험군은 37℃에서 24시간 동안 배양하였다. MIC 측정결과를 평가한 후, MBC(minimal bactericidal concentration) 시험을 실시하였으며, 이 시험에서는 MIC 시험에서 발육이 억제된 웰에 들어있던 액체배지를 TSA 고체배지에 접종한 후 37℃에서 24시간 동안 배양한 후 결과를 확인하였다.The MIC (Minimum Inhibitory Concentration) test was performed on a 96-well microtiter plate using liquid medium dilution. Specifically, a portion of 100 μl of a double-strength Muller-Hinton liquid medium (MB Cell, LA, CA) containing 5% DMSO was added to a 96-well microtiter plate, Lavender essential oil was set at 2% to 0.0156% (v / v), dispensed into 96-well microtiter plates, and 100 쨉 l of a pathogenic bacterial suspension was inoculated into all wells. In order to more objectively evaluate the results, positive control containing pathogenic bacteria and liquid bait, and negative control containing lavender essential oil and liquid bait were also prepared. The control and experimental groups were maintained at 37 ° C for 24 hours Lt; / RTI > After the MIC assay was evaluated, the MBC (minimal bactericidal concentration) test was performed. In this test, the liquid medium contained in the well-suppressed wells in the MIC test was inoculated into the TSA solid medium and cultured at 37 ° C for 24 hours And the results were confirmed.
실시예Example 1. 라벤더 1. Lavender 에센셜Essential 오일 처리에 따른 애완 거북으로부터 분리한 Separated from pet turtles by oil treatment 병원hospital 성 세균에 대한 항균 활성 확인Identification of antimicrobial activity against sex bacteria
본 실시예 1에서는 라벤더 에센셜 오일 처리에 따른 애완 거북으로부터 분리한 병원성 세균인 에어로모나스 캐비애(Aeromonas caviae), 에어로모나스 드하켄시스(Aeromonas dhakensis), 에어로모나스 하이드로필라(Aeromonas hydrophila) 및 살모넬라 엔테리카(Salmonella enterica)에 대해 항균 활성을 측정하였다. 그 결과, 하기 표 1에 개시한 바와 같이 라벤더 에센셜 오일은 상기 4종의 병원성 세균에 대해 농도의존적으로 강한 항균 활성을 나타내었다. 또한, 상기 4종의 병원성 세균의 항생제 감수성(Antibiotic susceptibility)을 측정한 결과, 3종의 에어로모나스 속(Aeromonas sp.) 균주들 중에 에어로모나스 캐비애 AC2, 에어로모나스 드하켄시스 AD2 및 에어로모나스 하이드로필라 AH1 균주가 11개의 항생제 중 6~10개의 항생제에 대해 저항성을 나타내었으며, 살모넬라 엔테리카(Salmonella enterica)는 S2, S3 및 S4 균주가 11개의 모든 항생제에 대해 감수성을 나타내었다(표 2).In Example 1, a pathogenic bacterium isolated from a pet turtle by treatment with lavender essential oil, Aeromonas cavaea ( Aeromonas caviae), Pseudomonas aero de Hakan sheath (Aeromonas dhakensis), Pseudomonas aero dihydro-pillar (Aeromonas hydrophila , and Salmonella enterica . As a result, as shown in Table 1 below, lavender essential oil exhibited a strong antimicrobial activity against the four pathogenic bacteria in a concentration-dependent manner. In addition, the antibiotic susceptibility of the four pathogenic bacteria was measured. As a result, three kinds of Aeromonas spp. ( Aeromonas Among the strains, Aeromonas caviae AC2, Aeromonas de Hansensis AD2 and Aeromonas hydrofilera strain AH1 showed resistance against 6 to 10 antibiotics among 11 antibiotics, and Salmonella enterica S2, S3, and S4 strains were susceptible to all 11 antibiotics (Table 2).
AMP는 암피실린(ampicillin); AMO는 아목시실린(amoxicillin); FOX는 세폭시틴(cefoxitin); KF는 세파로신(cephalothin); CRO는 세프트리약손(ceftriaxone); IMI는 이미페넴(imipenem); GEN은 겐타마이신(gentamicin); CIP는 시프로플록사신(ciprofloxacin); S는 스트렙토마이신(streptomycin); NXA는 날리딕스산(nalidixic acid); AK는 아미카신(amikacin)이며, S는 감수성 있는(sensitive), I는 중간(intermediate); R은 저항성 있는(resistant) 것을 의미한다.AMP is ampicillin; AMO is amoxicillin; FOX is cefoxitin; KF is cephalothin; CRO is ceftriaxone; IMI is imipenem; GEN is gentamicin; CIP is ciprofloxacin; S is streptomycin; NXA is nalidixic acid; AK is amikacin, S is sensitive, I is intermediate; R means resistant.
실시예Example 2. 라벤더 2. Lavender 에센셜Essential 오일 처리에 따른 애완 거북으로부터 분리한 병원성 세균에 대한 MRC index, MRC index for pathogenic bacteria isolated from pet turtle by oil treatment, MICMIC 및 MBC 확인 And MBC confirmation
본 실시예 2에서는 라벤더 에센셜 오일 처리에 따른 애완 거북으로부터 분리한 병원성 세균인 에어로모나스 캐비애(Aeromonas caviae), 에어로모나스 드하켄시스(Aeromonas dhakensis), 에어로모나스 하이드로필라(Aeromonas hydrophila) 및 살모넬라 엔테리카(Salmonella enterica)에 대해 다중항생제내성 지표(MRC index), 최소발육저지농도(MIC) 및 최소살균농도(MBC)를 측정하였다. 그 결과, 하기 표 3에 개시한 바와 같이 4종의 세균 중 에어로모나스 캐비애(Aeromonas caviae)에서 MAR 지표 값이 가장 높았으며, 살모넬라 엔테리카(Salmonella enterica)가 가장 낮은 MAR 지표 값을 나타내었다. 또한, 상기 4종의 세균들은 MAR 지표 값이 0.36~0.91로, 항균제가 자주 사용된 고위험 오염원으로부터 세균이 생존할 수 있음을 의미하는 MAR 지표 값(0.2)보다 높은 것을 확인할 수 있었다.In Example 2, a pathogenic bacterium isolated from a pet turtle by treatment with lavender essential oil, Aeromonas cavaea ( Aeromonas caviae), Pseudomonas aero de Hakan sheath (Aeromonas dhakensis), Pseudomonas aero dihydro-pillar (Aeromonas (MRC) index, minimum inhibitory concentration (MIC), and minimum bactericidal concentration (MBC) were measured for S. hydrophila and Salmonella enterica . As a result, as shown in Table 3 below, the MAR index value was highest in Aeromonas caviae among the four bacteria, and Salmonella enterica showed the lowest MAR index value. In addition, the MAR index values of the four bacteria were 0.36-0.91, which was higher than the MAR index (0.2), which means that bacteria can survive the high-risk pollutants frequently used.
또한, 라벤더 에센셜 오일의 애완 거북으로부터 분리한 병원성 세균인 에어로모나스 캐비애, 에어로모나스 드하켄시스, 에어로모나스 하이드로필라 및 살모넬라 엔테리카에 대한 MIC 값은 대부분 0.5~1%(v/v)였으며, MBC 측정에서도 마찬가지로 에어로모나스 캐비애, 에어로모나스 드하켄시스, 에어로모나스 하이드로필라 및 살모넬라 엔테리카에 대해 대부분 0.5~2%(v/v)인 것으로 확인되었다. 또한, 항균 물질이 MBC 값이 MIC 값의 4배 이하인 경우, 살균 효과가 있는 것으로 간주되기 때문에, 라벤더 에센셜 오일이 살균 또는 정균 효과가 있는지 확인하기 위해, MBC/MIC 값을 계산한 결과, 1~2인 것으로 확인되었다.In addition, the MIC values for aeromonas cavaea, aeromonas dehaksensis, aeromonas hydro pila and salmonella enterica, which are pathogenic bacteria isolated from pet turtle of lavender essential oil, were 0.5 ~ 1% (v / v) In MBC measurement, it was confirmed that it was mostly 0.5 to 2% (v / v) for Aeromonas cavaea, Aeromonas de Hacencis, Aeromonas hydro pila and Salmonella enterica. In addition, MBC / MIC values were calculated to determine whether the antibacterial substance had a bactericidal or bacteriostatic effect on lavender essential oil because MBC value was considered to be sterilizing effect when the MBC value was less than 4 times the MIC value. As a result, 2.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170175619A KR101995394B1 (en) | 2017-12-20 | 2017-12-20 | Antimicrobial composition against pet turtle-borne pathogenic bacteria containing lavender essential oil as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170175619A KR101995394B1 (en) | 2017-12-20 | 2017-12-20 | Antimicrobial composition against pet turtle-borne pathogenic bacteria containing lavender essential oil as effective component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190074350A KR20190074350A (en) | 2019-06-28 |
| KR101995394B1 true KR101995394B1 (en) | 2019-07-02 |
Family
ID=67066068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170175619A KR101995394B1 (en) | 2017-12-20 | 2017-12-20 | Antimicrobial composition against pet turtle-borne pathogenic bacteria containing lavender essential oil as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101995394B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102118546B1 (en) | 2020-02-03 | 2020-06-03 | 허브아일랜드영농조합법인 | Nano liposome herbal complex extract composition having stress relief, concentration enhancement and respiratory tonic effects and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015042410A1 (en) | 2013-09-19 | 2015-03-26 | Skirdle, Llc | Antimicrobial compositions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101626048B1 (en) * | 2009-11-26 | 2016-06-01 | (주)아모레퍼시픽 | Antibacterial detergent composition |
| KR20160118425A (en) * | 2015-04-01 | 2016-10-12 | 주식회사 불스원 | Antimicrobial and antifungal compositions comprising essential oils |
-
2017
- 2017-12-20 KR KR1020170175619A patent/KR101995394B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015042410A1 (en) | 2013-09-19 | 2015-03-26 | Skirdle, Llc | Antimicrobial compositions |
Non-Patent Citations (3)
| Title |
|---|
| J. Vet. Med. Sci., 79(5), pp. 921-926, 2017.04.10 |
| Journal of Applied Microbiology, Volume86, Issue6, pp. 985-990, 2001.12.25* |
| Letters in Applied Microbiology, Volume47, Issue3, Pages 167-173, 2008.08.27* |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102118546B1 (en) | 2020-02-03 | 2020-06-03 | 허브아일랜드영농조합법인 | Nano liposome herbal complex extract composition having stress relief, concentration enhancement and respiratory tonic effects and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190074350A (en) | 2019-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hassan et al. | Antimicrobial activity of some plant extracts having hepatoprotective effects | |
| Akinsulire et al. | In vitro antimicrobial activity of crude extracts from plants Bryophyllum pinnatum and Kalanchoe crenata | |
| Fagbemi et al. | Evaluation of the antimicrobial properties of unripe banana (Musa sapientum L.), lemon grass (Cymbopogon citratus S.) and turmeric (Curcuma longa L.) on pathogens | |
| Jeyachandran et al. | Antibacterial activity of stem extracts of Tinospora cordifolia (Willd) Hook. f & Thomson | |
| Nassima et al. | Antimicrobial and antibiofilm activities of phenolic compounds extracted from Populus nigra and Populus alba buds (Algeria) | |
| Akharaiyi et al. | Antibacterial effect of Terminalia catappa on some selected pathogenic bacteria | |
| Titilope et al. | In-vitro antimicrobial activities of Euphorbia hirta against some clinical isolates | |
| Ghudhaib et al. | Effect of ellagic acid on some types of pathogenic bacteria | |
| Al-Shuneigat et al. | Effects of wild Thymus vulgaris essential oil on clinical isolates biofilm-forming bacteria | |
| Adam et al. | Antibacterial activity of Ocimum basilicum (Rehan) leaf extract against bacterial pathogens in Sudan | |
| Bhuvaneswari et al. | Inhibitory concentrations of Lawsonia innermis dry powder for urinary pathogens | |
| Latha et al. | Pharmacological screening of methanolic extract of Ixora species | |
| Aliyu et al. | Antimicrobial activity of Sabulun Salo a local traditional medicated Soap | |
| KR101995394B1 (en) | Antimicrobial composition against pet turtle-borne pathogenic bacteria containing lavender essential oil as effective component | |
| CN110742926B (en) | Natural composition for inhibiting growth of pseudomonas aeruginosa as well as preparation method and application thereof | |
| Jafri et al. | In vitro efficacy of clove oil and eugenol against Staphylococcus spp and Streptococcus mutans on hydrophobicity, hemolysin production and biofilms and their synergy with antibiotics | |
| Ghazi et al. | Investigation of Antibacterial Effect of Cuminum cyminum and Carum carvi against Streptococcus mutans and Streptococcus pyogenes | |
| Abdullah et al. | Study effect of plant extraction for Cuscutaeuropaea (Dodder) against two species of bacteria Staphylococcus aureusand Escherichia coli | |
| Gülbandilar | Antimicrobial activities of propolis samples collected from different provinces of Turkey | |
| Ponmurugan et al. | Antibacterial activity of green tea leaves | |
| KR101919499B1 (en) | Antimicrobial composition against pathogenic super-bacteria containing propolis and alpha-pinene | |
| Nefefe et al. | Antimicrobial activities of essential oils from Southern Africa against selected bacterial and fungal organisms | |
| Roebiakto | The Effectiveness of Kirinyuh (Chromolaena odorata L.) Leaf Essential oil as an Antibacterial Staphylococcus aureus and Escherichia coli | |
| Pirzada et al. | The Disinfectant Properties of Suspensions of Herbal Extracts: An Antibacterial Study against Escherichia Coli and Staphylococcus Aureus | |
| KR101867271B1 (en) | Composition comprising of plant extract for hygienic band having antimicrobial activity and hygienic band using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |